单细胞RNA测序技术在胶质母细胞瘤研究中的应用

Application of Single Cell RNA Sequencing in Glioblastoma Research

胶质母细胞瘤是成人脑部最常见的原发恶性肿瘤,尽管近年来在改善预后方面做出了巨大的努力,其中位生存期仍低于20个月,且存活时间超过20个月的患者不到5%。胶质母细胞瘤的标准治疗方案为最大限度的手术切除,联合放疗及替莫唑胺化疗。单细胞RNA测序(scRNA-seq)技术精准分析每个独特的细胞,使我们能够更好地理解肿瘤的异质性、肿瘤细胞的演化过程、肿瘤免疫微环境中各类细胞的特殊功能及细胞间相互作用,从而为临床的个体化治疗提供新思路。该综述重点关注scRNA-seq技术在胶质母细胞瘤的异质性、肿瘤免疫微环境、细胞通讯以及治疗研究中的应用。

Glioblastoma is the most common primary malignant tumor of brain in adults.Although great efforts have been made to improve prognosis in recent years,the median survival is still less than 20months,and less than 5%of patients survive longer than 20months.The standard treatment is maximum surgical excision combined with radiotherapy and temozolomide chemotherapy.Single cell RNA sequencing(scRNA-seq)technology accurately analyzes each unique cell,enabling us to better understand the heterogeneity of tumors,the evolution process of tumor cells,the special functions of various types of cells in the immune microenvironment,and the interactions between cells,thus providing new ideas for personalized clinical therapy.This review focuses on the application of scRNA-seq in the study of glioblastoma heterogeneity,tumor immune microenvironment,cell communication and treatment.